|Bid||51.550 x 300|
|Ask||51.630 x 200|
|Day's Range||50.860 - 51.850|
|52 Week Range||45.310 - 71.320|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 7, 2018 - Feb 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||64.71|
Seattle Genetics, Inc. highlighted today the progress of its pipeline of antibody-drug conjugates at the 36th Annual J.P. Morgan Healthcare Conference. Through both internal efforts and that of its collaborators, the company’s ADC technology is being employed in more than 20 programs in clinical trials, including multiple late-state development programs across hematologic malignancies and solid tumors....
Merck's Keytruda receives approval in Japan for bladder cancer. Seattle Genetics' Adcetris and Novartis' Kisqali get regulatory status updates from the FDA.
Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.
Seattle Genetics' supplemental Biologics License Application for the label expansion of its lymphoma drug, Adcetris, was accepted by the FDA and granted priority review.
Seattle Genetics, Inc. announced today that the U.S. Food and Drug Administration has accepted for filing a supplemental Biologics License Application for ADCETRIS in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Seattle Genetics, Inc. Here are 5 ETFs with the largest exposure to SGEN-US. Comparing the performance and risk of Seattle Genetics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Seattle Genetics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Seattle Genetics, Inc. – ImmunoGen, Inc., Celldex Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., Pfizer Inc. and Progenics Pharmaceuticals, Inc. (IMGN-US, CLDX-US, SPPI-US, PFE-US and PGNX-US) that have also reported ... Read more (Read more...)
Seattle Genetics, Inc. announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 10:30 a.m.
NEW YORK, NY / ACCESSWIRE / December 15, 2017 / Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower, ...
Seattle Genetics, Inc. and Bristol-Myers Squibb Company today highlighted updated interim results from an ongoing phase 1/2 clinical trial evaluating the combination of ADCETRIS and Opdivo in relapsed or refractory classical Hodgkin lymphoma at the 59th American Society of Hematology Annual Meeting and Exposition taking place in Atlanta, Georgia, December 9-12, 2017.
Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc. today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology annual meeting on Sunday, December 10, 2017.
Seattle Genetics, Inc. today highlighted final five-year survival results from a phase 1 clinical trial evaluating ADCETRIS in mature T-cell lymphoma at the 59th American Society of Hematology Annual Meeting and Exposition taking place in Atlanta, Georgia, December 9-12, 2017.
Seattle Genetics, Inc. today highlighted updated results from the phase 3 ALCANZA clinical trial evaluating ADCETRIS in CD30-expressing cutaneous T-cell lymphoma at the 59th American Society of Hematology Annual Meeting and Exposition taking place in Atlanta, Georgia, December 9-12, 2017.
Seattle Genetics, Inc. today announced updated data from an ongoing phase 1 clinical trial evaluating ladiratuzumab vedotin in patients with metastatic triple negative breast cancer at the 2017 San Antonio Breast Cancer Symposium , taking place December 5-9, 2017.
In November 2017, the U.S. Food and Drug Administration (or FDA) granted United Therapeutics’ (UTHR) Adcirca Pediatric exclusivity until May 21, 2018.
Seattle Genetics, Inc. announced today that the company will webcast an investor and analyst event on Monday, December 11, 2017 during the 59th American Society of Hematology Annual Meeting in Atlanta, GA.